Algal Oil (Schizochytrium sp.).

Fish oil and Schizochytrium oil deliver the same molecule, docosahexaenoic acid, differing in the ratio of EPA to DHA and in the source organism. Taking both raises total long-chain omega-3 intake rather than adding a distinct mechanism. Total intake across all sources is the figure that matters.

Most Schizochytrium oils are DHA-dominant with a modest EPA share, while marine fish oils generally carry more EPA. Combining them fills out both ends of the long-chain omega-3 profile. The two are interchangeable at the level of the molecule delivered, which is the whole point of the algal route.

Algal oil from Schizochytrium is a DHA source. Any separate DHA supplement adds to the same pool. Stacking them is a dose question rather than a synergy. This is worth stating plainly so that combined intake is not double-counted as two different things.

Lecithin lowers interfacial tension and keeps oil droplets fine and dispersed, which increases the surface available to pancreatic lipase. It is used in emulsified and chewable algal oil formats for exactly that reason. It also supplies phospholipid into which DHA is esterified in tissue.

Carnosic acid and carnosol are lipid-soluble phenolics that slow the radical chain reaction in a highly unsaturated oil. DHA carries six double bonds and is the most oxidation-prone common dietary fatty acid, so an oil this unsaturated is routinely stabilised. Rosemary extract is a common choice alongside tocopherols.

Mixed tocopherols supply gamma and delta forms alongside alpha, and the non-alpha forms are the more effective chain-breakers in a bulk oil phase. They are added before the oil is exposed to oxygen. The role is protecting the oil, which is a formulation function and separate from any nutritional contribution.

Long-chain omega-3s shift eicosanoid output toward less aggregatory species, and garlic organosulfur compounds reduce platelet aggregation in laboratory measures. Both act on the same endpoint, so combining them is additive by construction. Anyone on anticoagulant medicine should raise the combination with their prescriber.

Evening primrose oil supplies gamma-linolenic acid, which is elongated into the omega-6 series, while algal DHA occupies the omega-3 side of the same desaturase and elongase machinery. Formulas carrying both are deliberately balancing the two families rather than pushing one. The competition is at the enzyme level and applies to conversion, not to preformed DHA already supplied.

A high linoleic acid intake occupies delta-6 desaturase and pushes the shared pathway toward the omega-6 series. Supplying preformed DHA sidesteps that bottleneck for DHA specifically. The competition still shapes what the rest of the diet converts.

Copper cycles between oxidation states and catalyses the breakdown of lipid hydroperoxides into radicals that propagate the peroxidation chain. Trace copper is a known driver of rancidity in highly unsaturated oils. Chelators and metal exclusion during processing exist to hold this in check, so co-formulating an unchelated copper salt into an algal oil works against them.

Catechins are hydrophilic polyphenols that act at the oil-water interface and can chelate transition metals as well as scavenge radicals. In an emulsified oil that interface is where a large share of oxidation starts. The pairing is a stability rationale. It is not a claim about combined effects in the body.

Bromelain is a cysteine protease included in some lipid and joint-directed blends. Its relevance to an algal oil is formulation company rather than a shared pathway. There is no established mechanism linking it to long-chain omega-3 handling, and it is listed at low confidence for that reason.